Financhill
Back

Eyenovia Quote, Financials, Valuation and Earnings

Eyenovia Price Quote

$0.11
+0.00 (+4.66%)
(Updated: November 23, 2024 at 5:34 AM ET)

Eyenovia Key Stats

Sell
21
Eyenovia (EYEN) is a Sell

Day range:
$0.10 - $0.12
52-week range:
$0.08 - $2.57
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
183.99
P/B ratio:
2.5%

Volume:
29.6M
Avg. volume:
6.9M
1-year change:
-92.03%
Market cap:
$9.3M
Revenue:
$3.8K
EPS:
$-0.71

How Much Does Eyenovia Make?

  • How Much Are Eyenovia's Sales Annually?
    EYEN Revenues are $3.8K
  • How Much Profit Does Eyenovia's Make A Year?
    EYEN net income is -$27.3M

Is Eyenovia Growing As A Company?

  • What Is Eyenovia's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.36%
  • What Is Eyenovia's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Eyenovia Stock Price Performance

  • Did Eyenovia Stock Go Up Last Month?
    Eyenovia share price went down by -80.18% last month
  • Did EYEN's Share Price Rise Over The Last Year?
    EYEN share price fell by -92.03% over the past 1 year

What Is Eyenovia 52-Week High & Low?

  • What Is Eyenovia’s 52-Week High Share Price?
    Eyenovia has traded as high as $2.57 over the past 52 weeks
  • What Is Eyenovia’s 52-Week Low Share Price?
    Eyenovia has traded as low as $0.08 over the past 52 weeks

Eyenovia Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Eyenovia?

  • How Much Debt Does Eyenovia Have?
    Total long term debt quarterly is $11.6M
  • How Much Cash Does Eyenovia Have?
    Cash and short term investments quarterly total is $7.2M
  • What Is Eyenovia’s Book Value Per Share?
    Book value per share is 0.04

Is Eyenovia Cash Flow Positive?

  • What Is EYEN Cash Flow From Operations?
    Cash flow from operations (TTM) is -$30.3M
  • What Is Eyenovia’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $17.1M
  • What Is Eyenovia’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$306.7K

Eyenovia Return On Invested Capital

  • Is Management Doing A Good Job?
    EYEN return on invested capital is -195.21%
  • What Is Eyenovia Return On Assets?
    ROA measures how assets are converting to revenues and is -143.72%
  • What Is EYEN Return On Equity?
    ROE is a measure of profitability and is -676.86%

Eyenovia Earnings Date & Stock Price

  • What Is Eyenovia's Stock Price Today?
    A single share of EYEN can be purchased today for 0.11
  • What Is Eyenovia’s Stock Symbol?
    Eyenovia trades on the nasdaq under the ticker symbol: EYEN
  • When Is Eyenovia’s Next Earnings Date?
    The next quarterly earnings date for Eyenovia is scheduled on March 18, 2025
  • When Is EYEN's next ex-dividend date?
    Eyenovia's next ex-dividend date is November 25, 2024
  • How To Buy Eyenovia Stock?
    You can buy Eyenovia shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

Eyenovia Competitors

  • Who Are Eyenovia's Competitors?
    Below is a list of companies who compete with Eyenovia or are related in some way:
    • Amneal Pharmaceuticals Inc (AMRX)
    • Aptevo Therapeutics Inc (APVO)
    • Johnson & Johnson (JNJ)
    • Merck & Co Inc (MRK)
    • TFF Pharmaceuticals Inc (TFFP)

Eyenovia Dividend Yield

  • What Is EYEN Dividend Yield?
    Eyenovia’s dividend yield currently is 0%
  • What Is Eyenovia’s Payout Ratio?
    Eyenovia’s payout ratio is 0%
  • When Did Eyenovia Last Pay A Dividend?
    The latest dividend pay date is November 25, 2024
  • What Is Eyenovia’s Dividend Per Share?
    Eyenovia pays a dividend of $0.00 per share

Eyenovia Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -10%
Revenue: 35.64% -98.55%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 4
Sell Recommendations: 0
Price Target: 3.50
Upside from Last Price: 3152.79%

Major Shareholders

  • How many EYEN shares are owned by institutional investors?
    16.5M EYEN shares are owned by institutional investors
  • How many EYEN shares are owned by insiders?
    14M EYEN shares are owned by insiders